Ausgabe 2/2017
Inhalt (12 Artikel)
Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?
Peggy Gandia, Cyril Jaudet, Etienne Chatelut, Didier Concordet
Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus
Tian Yu, Elena Y. Enioutina, Hermine I. Brunner, Alexander A. Vinks, Catherine M. Sherwin
Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies
Amélie Marsot, Romain Guilhaumou, Camille Riff, Olivier Blin
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
Nianhang Chen, Simon Zhou, Maria Palmisano
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment
Amit Khatri, Sandeep Dutta, Thomas C. Marbury, Richard A. Preston, Lino Rodrigues Jr, Haoyu Wang, Walid M. Awni, Rajeev M. Menon
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
Francis Lévi, Abdoulaye Karaboué, Marie-Christine Etienne-Grimaldi, Gilles Paintaud, Christian Focan, Pasquale Innominato, Mohamed Bouchahda, Gérard Milano, Etienne Chatelut
Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis
Raju Subramanian, Xiaochun Zhu, M. Benjamin Hock, Bethlyn J. Sloey, Benjamin Wu, Sarah F. Wilson, Ogo Egbuna, J. Greg Slatter, Jim Xiao, Gary L. Skiles
Discrepancies between the Cockcroft–Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies
Pierre Delanaye, Fabrice Guerber, André Scheen, Timothy Ellam, Antoine Bouquegneau, Dorra Guergour, Christophe Mariat, Hans Pottel
Comment on: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
Kirollos S. Kamel, Paul K. L. Chin, Matthew P. Doogue, Murray L. Barclay
Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”
Stephan Glund, Paul Reilly, Joanne van Ryn, Joachim Stangier
Comment on: “Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”
Nuggehally R. Srinivas